Click here to join the case
LOS ANGELES, Aug. 13, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of MEI Pharma, Inc. ("MEI" or "the Company") (NASDAQ: MEIP) investors that acquired securities between August 18th, 2017 and July 1, 2020.
According to the lawsuit, throughout the Class Period the defendants made statements that were misleading and/or false and/or failed to disclose that: (1) MEI Pharma overstated the potential efficacy of Pracinostat as an acute myeloid leukemia (“AML”), treatment for the target population; (2) consequently, the Phase 3 Pracinostat Trial was unlikely to meet its primary endpoint of overall survival; (3) once revealed, all the foregoing was foreseeably likely to have a material negative impact on the financial condition of the Company’s and prospects for Pracinostat; and (4) as a result, public statements made by the Company were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar